Logo

Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

Share this

Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

Shots:

  • The P-III MONARCH 2 study involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 pre/peri- and postmenopausal women in a ratio (2:1) with HR+- HER2- metastatic breast cancer whose cancer progressed following endocrine therapy
  • The P-III MONARCH 2 study resulted in meetings 2EP of overall survival with no new observed safety signals. The P-III MONARCH study previously met its 1EPs i.e- improvement in PFS which serves as the basis for its approval in 50+ countries
  • Verzenio is a CDK 4 & 6 inhibitors which are activated by binding to D-cyclins- inhibiting Rb phosphorylation with blocking progression from G1 to S phase of the cell cycle resulting in senescence and apoptosis

Click here to­ read full press release/ article

Ref: Eli Lilly | Image: Eli Lilly


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions